Lantheus Holdings, Inc. (NASDAQ: LNTH) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $6.7B. The Maz Rating grades it against the other companies in its sector.
Lantheus Holdings, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $101.80, Lantheus Holdings, Inc. trades at 24.6x trailing earnings, 4.3x sales and 4.9x book value, with an EV/EBITDA of 13.3. Over the last twelve months it generated about $1.6B of revenue and $271M of net income. It runs a gross margin of 61.3%, an operating margin of 18.6% and a net margin of 17.3%. It shows return on equity of 21.7%, return on invested capital of 10.9% and a free cash flow yield of 5.9%. On the balance sheet: a debt-to-equity ratio of 0.04 and a current ratio of 3.25. Over the past 52 weeks the share price ranged from $51.84 to $111.86, with a beta of -0.06.
Lantheus Holdings, Inc. does not currently pay a dividend.
19 Wall Street analyst ratings cover the stock: 10 Buy and 9 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Lantheus Holdings, Inc. (LNTH) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.01% / 30% · (Cash+Inv) / Mkt Cap (36m) 11.9% / 30% · Interest income / Revenue 1.78% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.01% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 10.4% / 33% · Receivables / Mkt Cap (36m) 5.28% / 49% · Interest income / Revenue 1.78% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.01% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 10.4% / 33.33% · Receivables / Mkt Cap (24m) 5.28% / 33.33% · Interest income / Revenue 1.78% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 18.7% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 22.6% / 33.33% · Receivables / Avg Assets (4Q) 15.0% / 33.33% · Interest income / Revenue 1.78% / 5% | Pass |
| FTSE | Debt / Total Assets 0.02% / 33.33% · (Cash+ST Inv) / Total Assets 27.8% / 33.33% · (Cash+Recv) / Total Assets 41.9% / 33.33% · Interest income / Revenue 1.78% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Lantheus Holdings, Inc. (LNTH) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. Lantheus Holdings, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.78% of each dividend: Lantheus Holdings, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.